Frontlight ResearchEarly access
Macular degeneration trials in Germany
19 of 22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in GermanyPhase 2 Study of ADX-038 in Participants With Geographic Atrophy
- Where
- Bonn, Giessen, Köln, Mainz, Muenster, Munich, Sulzbach, Tuebingen
- Age
- 60 years and over
- People
- 240 worldwide
- Run by
- ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06990269 · EU 2025-521779-30-00 - Phase 2Taking peopleA Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
- Where
- Bonn, Freiburg im Breisgau, Hanover, Heidelberg, Neubrandenburg, Tübingen, Ulm
- Age
- 55 years to 64 years
- People
- 110 worldwide
- Run by
- Galimedix Therapeutics Inc
See details and how to joinNCT06659549 · EU 2024-519128-26-00 - Phase 2Taking peopleA Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
- Where
- Bonn, Ludwigshafen Am Rhein, Munster, Tuebingen
- Age
- 50 years and over
- People
- 272 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07441642 · EU 2025-523704-77-00 - Phase 3Taking peopleA Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
- Where
- Chemnitz, Duesseldorf, Goettingen, Hanover, Rostock, Wuerzburg
- Age
- 50 years and over
- People
- 250 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06847542 · EU 2024-516924-32-00 - Phase 3Taking peopleA Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- Where
- Berlin, Bonn, Duesseldorf, Frankfurt am Main, Goettingen, Hamburg, Heidelberg, Homburg, Ludwigshafen Am Rhein, Mainz, Marburg, Muenster, Munster, Neubrandenburg, Sulzbach, Ulm, Wuerzburg
- Age
- 50 years to 85 years
- People
- 975 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06541704 · EU 2023-509547-27-00 - Phase 2/3Taking peopleA Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Where
- Bonn, Goettingen, Hanover, Leipzig, Ludwigshafen Am Rhein, Muenster, Munster, Tuebingen
- Age
- 60 years and over
- People
- 274 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06635148 · EU 2022-500747-21-00 - Phase 3Taking peopleStudy to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- Where
- Berlin, Bonn, Freiburg im Breisgau, Goettingen, Hamburg, Hanover, Ludwigshafen Am Rhein, Luebeck, Muenster, Munich, Tuebingen, Ulm
- Age
- 50 years and over
- People
- 561 worldwide
- Run by
- AbbVie
See details and how to joinNCT07007065 · EU 2024-512298-28-00 - Phase 3Taking peopleExtension Study for the Port Delivery System With Ranibizumab (Portal)
- Where
- Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen Am Rhein, Muenster, Munich, Munster, Sulzbach, Tuebingen, Ulm
- Age
- 50 years and over
- People
- 1,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT03683251 · EU 2023-507131-38-00 - Phase 3Active, not recruitingSingle Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Where
- Düsseldorf, Frankfurt, Neubrandenburg
- Age
- 50 years and over
- People
- 480 worldwide
- Run by
- 4D Molecular Therapeutics
See details and how to joinNCT07064759 - Phase 2/3Taking peopleA Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- Where
- Hamburg, Münster
- Age
- 50 years and over
- People
- 960 worldwide
- Run by
- EyeBiotech Ltd.
See details and how to joinNCT07440225 - Phase 2Active, not recruitingORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
- Where
- Luebeck, Tuebingen
- Age
- 55 years and over
- People
- 225 worldwide
- Run by
- Gyroscope Therapeutics Limited
See details and how to joinNCT05481827 · EU 2024-510946-15-00 - Phase 3Taking peopleVitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
- Where
- Berlin, Bonn, Hamburg, Ludwigshafen Am Rhein, Muenster, Munich, Stuttgart, Sulzbach, Ulm, Würzburg
- Age
- 50 years to 120 years
- People
- 210 worldwide
- Run by
- King's College Hospital NHS Trust
See details and how to joinNCT04663750 · EU 2023-504751-28-00 - Phase 2Taking peopleStudy to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
- Where
- Aachen, Ahaus, Baden-Baden, Bonn, Duesseldorf, Frankfurt am Main, Marburg, Wuerzburg
- Age
- 55 years and over
- People
- 324 worldwide
- Run by
- ONL Therapeutics
See details and how to joinNCT06659445 · EU 2024-513174-22-00 - No phaseTaking peopleSafety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
- Where
- Hamburg, München, Stuttgart, Tübingen, Ulm
- Age
- 60 years and over
- People
- 70
- Run by
- Okuvision GmbH
See details and how to joinNCT07531927 - Phase 2/3Taking peopleA randomized double-masked, multicenter, 3 arm pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 in participants with neovascular age-related macular degeneration (NVAMD)
- Where
- Bonn, Frankfurt am Main, Hamburg, Hanover, Munich, Munster, Tuebingen
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Eyebiotech Limited
See details and how to join2025-524575-22-00 - No phaseEnrolling by invitationReal-time Acoustic Biofeedback for Enhancing Fixation Stability: A Proof-of-concept Study to Improve Ophthalmic Imaging Diagnostic Quality
- Where
- Göttingen
- Age
- 18 years and over
- People
- 22
- Run by
- University Medical Center Goettingen
See details and how to joinNCT07529041 - No phaseTaking peopleInternational Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study
- Where
- Hamburg, Sulzbach, Trier, Würzburg
- Age
- 55 years and over
- People
- 44 worldwide
- Run by
- VisionCare, Inc.
See details and how to joinNCT07164378 - No phaseNot yet taking people in GermanyThis Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Decisions About Treatment for Patients with a Specific Eye Disease (nAMD)
- Where
- Munich
- Age
- 18 years and over
- People
- 100
- Run by
- Johannes Schiefelbein
See details and how to joinNCT06817915 - Phase 2Not yet taking people in GermanyLong-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
- Where
- Bonn, Freiburg im Breisgau, Hamburg, Ludwigshafen Am Rhein, Muenster, Ulm
- Age
- 50 years and over
- People
- 865 worldwide
- Run by
- AbbVie
See details and how to joinNCT03999801 · EU 2023-505750-17-00